GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (STU:RYIS) » Definitions » Tax Rate %

Viracta Therapeutics (STU:RYIS) Tax Rate % : 0.00% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics Tax Rate %?

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Viracta Therapeutics's Tax Expense for the three months ended in Mar. 2024 was €0.00 Mil. Viracta Therapeutics's Pre-Tax Income for the three months ended in Mar. 2024 was €-8.41 Mil. Therefore, Viracta Therapeutics's Tax Rate % for the quarter that ended in Mar. 2024 was 0.00%.

Viracta Therapeutics Tax Rate % Historical Data

The historical data trend for Viracta Therapeutics's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viracta Therapeutics Tax Rate % Chart

Viracta Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Tax Rate %
- - - -

Viracta Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Viracta Therapeutics Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Viracta Therapeutics's Tax Rate % for the fiscal year that ended in Dec. 2023 is calculated as

Tax Rate %=Tax Expense (A: Dec. 2023 )/Pre-Tax Income (A: Dec. 2023 )
=0/-46.82
=0.00 %

Viracta Therapeutics's Tax Rate % for the quarter that ended in Mar. 2024 is calculated as

Tax Rate %=Tax Expense (Q: Mar. 2024 )/Pre-Tax Income (Q: Mar. 2024 )
=0/-8.41
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viracta Therapeutics Tax Rate % Related Terms

Thank you for viewing the detailed overview of Viracta Therapeutics's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.

Viracta Therapeutics (STU:RYIS) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (STU:RYIS) » Definitions » Tax Rate %
Comparable Companies
PIRS NRXP MRKR ENLV NCNA ORGS SRNEQ ABIO CADL RGLS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
VIRX:USA
Address
2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007
Website
https://www.viracta.com
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.

Viracta Therapeutics (STU:RYIS) Headlines

No Headlines